勘误：《丝状病毒进入抑制剂药效学评价的假病毒感染小鼠模型的建立》[《中国药理学通报》8 (2018) 200 - 208]的作者更正。
Erratum: Author correction to 'Establishment of pseudovirus infection mouse models for pharmacodynamics evaluation of filovirus entry inhibitors' [Acta Pharmaceutica Sinica B 8 (2018) 200-208].
作者信息
Chen Qing, Tang Ke, Zhang Xiaoyu, Chen Panpan, Guo Ying
机构信息
State Key Laboratory of Bioactive Substances and Function of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
出版信息
Acta Pharm Sin B. 2020 Aug;10(8):1586-1587. doi: 10.1016/j.apsb.2020.06.010. Epub 2020 Jun 29.
Abstract
[This corrects the article DOI: 10.1016/j.apsb.2017.08.003.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.apsb.2017.08.003。]
相似文献
1
Erratum: Author correction to 'Establishment of pseudovirus infection mouse models for pharmacodynamics evaluation of filovirus entry inhibitors' [Acta Pharmaceutica Sinica B 8 (2018) 200-208].勘误：《丝状病毒进入抑制剂药效学评价的假病毒感染小鼠模型的建立》[《中国药理学通报》8 (2018) 200 - 208]的作者更正。
Acta Pharm Sin B. 2020 Aug;10(8):1586-1587. doi: 10.1016/j.apsb.2020.06.010. Epub 2020 Jun 29.
2
Erratum: Author correction to "Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles" [Acta Pharmaceutica Sinica B 12 (2022) 1523-1533].勘误：《利用工程化ACE2细胞外囊泡中和SARS-CoV-2假病毒》[《中国药理学报B》12 (2022) 1523 - 1533]的作者更正。
Acta Pharm Sin B. 2023 Nov;13(11):4664-4666. doi: 10.1016/j.apsb.2023.08.007. Epub 2023 Aug 7.
3
Erratum: Author correction to "Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry" [Acta Pharmaceutica Sinica B 10 (2020) 789-798].勘误：“确定膳食补充剂辣椒素为拉沙病毒进入的抑制剂”[《中国药理学报B》10 (2020) 789 - 798]的作者更正。
Acta Pharm Sin B. 2024 Jul;14(7):3294. doi: 10.1016/j.apsb.2024.04.012. Epub 2024 Apr 18.
4
Erratum: Author correction to 'Approved HIV reverse transcriptase inhibitors in the past decade' [Acta Pharmaceutica Sinica B 12 (2022) 1567-1590].勘误：《过去十年中获批的HIV逆转录酶抑制剂》[《中国药理学报B》12 (2022) 1567 - 1590]的作者更正。
Acta Pharm Sin B. 2023 Aug;13(8):3581. doi: 10.1016/j.apsb.2023.06.004. Epub 2023 Jun 9.
5
Erratum: Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372].勘误：“用于NTRK融合癌的小分子原肌球蛋白受体激酶（TRK）抑制剂的研发”[《中国药理学报B》11 (2021) 355 - 372]的作者更正。
Acta Pharm Sin B. 2022 Jun;12(6):2963-2964. doi: 10.1016/j.apsb.2022.02.028. Epub 2022 Mar 2.
6
Erratum: Author correction to 'Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models' [Acta Pharmaceutica Sinica B 11(2021) 1903-1913].勘误：《VMY-2-95对小鼠及细胞模型中皮质酮诱导损伤的保护作用》[《中国药理学通报》11(2021) 1903 - 1913]的作者更正。
Acta Pharm Sin B. 2023 Feb;13(2):899-901. doi: 10.1016/j.apsb.2022.11.017. Epub 2022 Nov 17.
7
Erratum: Author correction to 'Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models' [Acta Pharmaceutica Sinica B 11 (2021) 1903-1913].勘误：《VMY-2-95对小鼠和细胞模型中皮质酮诱导损伤的保护作用》[《中国药理学报B》11 (2021) 1903-1913]的作者更正。
Acta Pharm Sin B. 2023 Aug;13(8):3579-3580. doi: 10.1016/j.apsb.2023.05.002. Epub 2023 May 7.
8
Erratum: Author correction to 'Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication' [Acta Pharmaceutica Sinica B 9 (2019) 769-781].勘误：《双环醇上调糖脂转运蛋白导致丙型肝炎病毒复制的自发限制》[《中国药理学报B》9 (2019) 769 - 781]的作者更正。
Acta Pharm Sin B. 2020 Jan;10(1):195-196. doi: 10.1016/j.apsb.2020.01.002. Epub 2020 Jan 20.
9
Erratum: Author correction to 'Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome' [Acta Pharmaceutica Sinica B 9 (2019) 734-744].勘误：对“药用植物小豆蔻明通过抑制NLRP3炎性小体预防脂多糖诱导的脓毒症休克”[《中国药理学报B》9 (2019) 734 - 744]一文作者的更正。
Acta Pharm Sin B. 2020 Dec;10(12):2433-2434. doi: 10.1016/j.apsb.2020.09.011. Epub 2020 Sep 24.
10
Erratum: Author correction to 'Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents' [Acta Pharmaceutica Sinica B 9 (2019) 335-350].勘误：《具有新型双重抗氧化机制的查尔酮类似物作为潜在抗缺血性中风药物的设计、合成及生物学评价》[《中国药理学报B》9 (2019) 335 - 350]的作者更正。
Acta Pharm Sin B. 2022 Aug;12(8):3451-3452. doi: 10.1016/j.apsb.2022.05.030. Epub 2022 May 31.
Zotero 插件